| Primary |
| Malaria Prophylaxis |
54.5% |
| Prophylaxis |
13.5% |
| Drug Use For Unknown Indication |
12.0% |
| Malaria |
9.1% |
| Product Used For Unknown Indication |
3.6% |
| Hypertension |
1.1% |
| Foreign Travel |
0.8% |
| Contraception |
0.6% |
| Hiv Infection |
0.6% |
| Plasmodium Falciparum Infection |
0.6% |
| Arrhythmia |
0.4% |
| Atrial Fibrillation |
0.4% |
| Babesiosis |
0.4% |
| Blood Pressure |
0.4% |
| Depression |
0.4% |
| Epilepsy |
0.4% |
| Anxiety |
0.3% |
| Bipolar Disorder |
0.3% |
| Blood Cholesterol Increased |
0.3% |
| Lyme Disease |
0.3% |
|
| Vomiting |
17.8% |
| Pyrexia |
8.5% |
| Urticaria |
8.0% |
| Weight Decreased |
6.8% |
| Rash |
5.9% |
| Malaria |
5.4% |
| Drug Exposure During Pregnancy |
4.6% |
| Nausea |
4.6% |
| Thrombocytopenia |
4.1% |
| Diarrhoea |
3.9% |
| Alopecia |
3.4% |
| Pharmaceutical Product Complaint |
3.4% |
| Abnormal Dreams |
3.2% |
| Malaise |
3.2% |
| Mouth Ulceration |
3.2% |
| Treatment Noncompliance |
3.2% |
| Tachycardia |
2.9% |
| Headache |
2.7% |
| Syncope |
2.7% |
| Psychotic Disorder |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
20.7% |
| Malaria Prophylaxis |
17.7% |
| Drug Use For Unknown Indication |
12.2% |
| Prophylaxis |
9.1% |
| Maternal Exposure Timing Unspecified |
6.1% |
| Drug Exposure During Pregnancy |
5.5% |
| Malaria |
4.3% |
| Multiple Myeloma |
4.3% |
| Pain |
2.4% |
| Psoriasis |
2.4% |
| Urinary Tract Infection |
2.4% |
| Crohn's Disease |
1.8% |
| Hiv Infection |
1.8% |
| Hiv Test Positive |
1.8% |
| Osteoporosis |
1.8% |
| Hyperlipidaemia |
1.2% |
| Hypertension |
1.2% |
| Intervertebral Discitis |
1.2% |
| Lyme Disease |
1.2% |
| Analgesia |
0.6% |
|
| Ototoxicity |
19.6% |
| Drug Interaction |
11.8% |
| Ventricular Septal Defect |
9.8% |
| Dermatitis Acneiform |
7.8% |
| Visual Impairment |
5.9% |
| Hallucination |
3.9% |
| Neuropathy |
3.9% |
| Normal Newborn |
3.9% |
| Poor Quality Sleep |
3.9% |
| Rash |
3.9% |
| Sepsis |
3.9% |
| Spermatozoa Abnormal |
3.9% |
| Thrombocytopenia |
3.9% |
| Aspartate Aminotransferase Increased |
2.0% |
| Cardiac Fibrillation |
2.0% |
| Clostridium Test Positive |
2.0% |
| Drug Exposure During Pregnancy |
2.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.0% |
| Exposure During Pregnancy |
2.0% |
| Foetal Exposure During Pregnancy |
2.0% |
|
| Concomitant |
| Malaria Prophylaxis |
18.8% |
| Septic Shock |
10.3% |
| Contraception |
8.5% |
| Product Used For Unknown Indication |
8.5% |
| Drug Use For Unknown Indication |
7.7% |
| Ankylosing Spondylitis |
6.8% |
| Pain |
4.3% |
| Hyperlipidaemia |
3.4% |
| Osteoporosis |
3.4% |
| Acne |
2.6% |
| Crohn's Disease |
2.6% |
| Deep Vein Thrombosis |
2.6% |
| Embolism Venous |
2.6% |
| Lyme Disease |
2.6% |
| Malaria |
2.6% |
| Medical Induction Of Coma |
2.6% |
| Menorrhagia |
2.6% |
| Plasmodium Falciparum Infection |
2.6% |
| Premenstrual Syndrome |
2.6% |
| Pulmonary Embolism |
2.6% |
|
| Deep Vein Thrombosis |
13.2% |
| Gallbladder Injury |
7.9% |
| Poor Quality Sleep |
7.9% |
| Aplasia Pure Red Cell |
5.3% |
| Drug Ineffective |
5.3% |
| Injury |
5.3% |
| Pruritus Generalised |
5.3% |
| Psychotic Disorder |
5.3% |
| Pulmonary Embolism |
5.3% |
| Thrombocytopenic Purpura |
5.3% |
| Urticaria |
5.3% |
| Visual Disturbance |
5.3% |
| Weight Increased |
5.3% |
| Arthralgia |
2.6% |
| Atrial Fibrillation |
2.6% |
| Fatigue |
2.6% |
| Hallucination |
2.6% |
| Headache |
2.6% |
| Hepatitis Cholestatic |
2.6% |
| Hepatocellular Injury |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
85.7% |
| Malaria Prophylaxis |
14.3% |
|
| Drug Interaction |
60.0% |
| Dermatitis Acneiform |
40.0% |
|
